{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:25:13Z","timestamp":1787027113281,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Dupilumab is the first biological treatment for atopic dermatitis (AD). Dupilumab-associated ocular surface disease (DAOSD) is one of the most commonly reported side effects in patients with AD during dupilumab treatment. This study aimed to identify risk factors for DAOSD in a real-world setting and construct a risk-scoring system for predicting DAOSD risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted for dupilumab-treated adult patients with AD between April 2019 and September 2023 at Yeouido St. Mary\u2019s Hospital in Korea. Patients aged \u226518\u00a0years who received dupilumab to treat AD were included. Univariate and multivariable logistic regression analyses were performed to determine independent risk factors for DAOSD. A risk scoring system was constructed to predict DAOSD risk based on the adjusted odd ratios of significant variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 97 dupilumab-treated patients, 28 (28.9%) developed DAOSD. Among them, three (10.7%) patients discontinued dupilumab due to ocular side effects. In the multivariable analysis, older age, history of conjunctivitis, and a baseline Eczema Area and Severity Index (EASI) score \u226528 were independent risk factors for developing DAOSD. Using these variables, a risk-scoring system was constructed. The predicted DAOSD risks for AD patients with 0, 1, 2, 3, 4, and 5 points were 5.8%, 14.2%, 30.7%, 54.3%, 76.2%, and 89.6%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, the patient\u2019s age, history of conjunctivitis, and higher baseline EASI score were significantly associated with DAOSD. This risk-scoring system would help identify high-risk patients requiring more caution when initiating dupilumab treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1425550","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T01:07:10Z","timestamp":1722474430000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis"],"prefix":"10.3389","volume":"15","author":[{"given":"Sunyoung","family":"Shim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sun","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/cea.14461","article-title":"Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy","volume":"54","author":"Achten","year":"2024","journal-title":"Clin. Exp. Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1111\/all.15717","article-title":"Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis","volume":"78","author":"Achten","year":"2023","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"adv00666","DOI":"10.2340\/actadv.v102.1128","article-title":"Identification of risk factors for dupilumab-associated ocular surface disease in patients with atopic dermatitis","volume":"102","author":"Achten","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R. D."},{"key":"B5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br. J. Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry","volume":"84","author":"Ariens","year":"2021","journal-title":"J. Am. Acad. Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/ddg.13809","article-title":"Management of dupilumab-associated conjunctivitis in atopic dermatitis","volume":"17","author":"Aszodi","year":"2019","journal-title":"J. Dtsch. Dermatol Ges."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br. J. Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"key":"B12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/all.14610","article-title":"Treatment-emergent adverse events in dupilumab-treated patients with allergic diseases: a meta-analysis","volume":"76","author":"Chen","year":"2021","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/ajd.13924","article-title":"Dupilumab-associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting","volume":"63","author":"Foley","year":"2022","journal-title":"Australas. J. Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S28-S36","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J. Am. Acad. Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J. Am. Acad. Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"adv00483","DOI":"10.2340\/00015555-3842","article-title":"Transient increase in circulating basophils and eosinophils in dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"101","author":"Katsuta","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-associated adverse events during treatment of allergic diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017","volume":"184","author":"Laughter","year":"2021","journal-title":"Br. J. Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40272-022-00531-0","article-title":"Dupilumab treatment in children aged 6-11 Years with atopic dermatitis: a multicentre, real-life study","volume":"24","author":"Napolitano","year":"","journal-title":"Paediatr. Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e15588","DOI":"10.1111\/dth.15588","article-title":"A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis","volume":"35","author":"Napolitano","year":"","journal-title":"Dermatol Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.18176\/jiaci.0481","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience","volume":"30","author":"Nettis","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e15415","DOI":"10.1111\/dth.15415","article-title":"Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: retrospective chart analysis from a single tertiary care center","volume":"35","author":"Parmar","year":"2022","journal-title":"Dermatol Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae","volume":"35","author":"Popiela","year":"2021","journal-title":"Eye (Lond)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinforma."},{"key":"B27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jdv.17832","article-title":"Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey","volume":"36","author":"Ronnstad","year":"2022","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","article-title":"Dupilumab for treatment of atopic dermatitis","volume":"11","author":"Seegraber","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/all.14631","article-title":"Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis","volume":"76","author":"Siegels","year":"2021","journal-title":"Allergy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"Stander","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/S0140-6736(17)31192-3","article-title":"Dupilumab for atopic dermatitis","volume":"389","author":"Strowd","year":"2017","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J. Am. Acad. Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study","volume":"35","author":"Touhouche","year":"2021","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jaad.2019.12.039","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting","volume":"82","author":"Uchida","year":"2020","journal-title":"J. Am. Acad. Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bjo.82.1.82","article-title":"Systemic and local immunological features of atopic dermatitis patients with ocular complications","volume":"82","author":"Uchio","year":"1998","journal-title":"Br. J. Ophthalmol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J. Stat. Softw."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1425550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T01:07:12Z","timestamp":1722474432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1425550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":39,"alternative-id":["10.3389\/fphar.2024.1425550"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1425550","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"article-number":"1425550"}}